Biomarkers /
ERBB2 Loss
Back to Biomarkers List
Overview
ERBB2 Loss is present in 0.02% of AACR GENIE cases, with ovarian neoplasm, breast carcinoma, sarcoma, head and neck cancer, and large cell neuroendocrine carcinoma having the greatest prevalence [4].
Biomarker-Directed Therapies
ERBB2 Loss is a predictive biomarker for use of ribociclib, abemaciclib, aromatase inhibitor, everolimus, exemestane, fulvestrant, letrozole, palbociclib, alpelisib, anastrozole, atezolizumab, nab-paclitaxel, olaparib, and talazoparib in patients.
There are 14 FDA approvals and 11 NCCN guidelines that support the use of a targeted therapy based on the presence of ERBB2 Loss.
Breast carcinoma has the most therapies targeted against ERBB2 Loss or its related pathways [5].
Abemaciclib +
Everolimus +
Letrozole +
Olaparib +
Breast Carcinoma -
Talazoparib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for adult patients with deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. |
Abemaciclib + Aromatase Inhibitor +
Abemaciclib + Fulvestrant +
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
Anastrozole + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Aromatase Inhibitor + Ribociclib +
Atezolizumab + Nab-Paclitaxel +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA) | |
| Note: Atezolizumab (TECENTRIQ®, Genentech Inc.) is approved in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) |
Exemestane + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Fulvestrant + Palbociclib +
Letrozole + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN, MCG), Recurrent (NCCN, MCG) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. |
Clinical Trials
ERBB2 Loss serves as an inclusion eligibility criterion in 712 clinical trials, of which 590 are open and 122 are closed. Of the trials that contain ERBB2 Loss as an inclusion criterion, 11 are early phase 1 (9 open), 188 are phase 1 (143 open), 103 are phase 1/phase 2 (89 open), 289 are phase 2 (241 open), 10 are phase 2/phase 3 (9 open), 79 are phase 3 (72 open), 2 are phase 4 (1 open), and 30 are no phase specified (26 open).
Trials with ERBB2 Loss in the inclusion eligibility criteria most commonly target breast carcinoma, malignant solid tumor, non-small cell lung carcinoma, ovarian carcinoma, and colorectal carcinoma [5].
Paclitaxel, pembrolizumab, carboplatin, fulvestrant, and palbociclib are the most frequent therapies in trials with ERBB2 Loss as an inclusion criteria [5].
Significance of ERBB2 Loss in Diseases
Breast Carcinoma +
ERBB2 is mutated in 14.05% of breast carcinoma patients with ERBB2 Loss present in 0.02% of all breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 671 clinical trials for breast carcinoma, of which 555 are open and 116 are closed. Of the trials that contain ERBB2 Loss and breast carcinoma as inclusion criteria, 11 are early phase 1 (9 open), 180 are phase 1 (137 open), 100 are phase 1/phase 2 (87 open), 278 are phase 2 (230 open), 9 are phase 2/phase 3 (8 open), 68 are phase 3 (63 open), 2 are phase 4 (1 open), and 23 are no phase specified (20 open) [5].
Everolimus, exemestane, abemaciclib, aromatase inhibitor, fulvestrant, alpelisib, anastrozole, ribociclib, palbociclib, atezolizumab, nab-paclitaxel, letrozole, olaparib, and talazoparib are currently approved for use in patients with ERBB2 Loss in breast carcinoma [5].
Paclitaxel, fulvestrant, and carboplatin are the most frequent therapies in trials for breast carcinoma that contain ERBB2 Loss [5].
Malignant Solid Tumor +
ERBB2 is mutated in 2.2% of malignant solid tumor patients [4].
ERBB2 Loss is an inclusion criterion in 83 clinical trials for malignant solid tumor, of which 68 are open and 15 are closed. Of the trials that contain ERBB2 Loss and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 61 are phase 1 (48 open), 19 are phase 1/phase 2 (17 open), and 2 are phase 2 (2 open) [5].
Paclitaxel, carboplatin, and spartalizumab are the most frequent therapies in trials for malignant solid tumor that contain ERBB2 Loss [5].
Non-Small Cell Lung Carcinoma +
ERBB2 is mutated in 4.12% of non-small cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 68 clinical trials for non-small cell lung carcinoma, of which 52 are open and 16 are closed. Of the trials that contain ERBB2 Loss and non-small cell lung carcinoma as inclusion criteria, 39 are phase 1 (27 open), 18 are phase 1/phase 2 (14 open), and 11 are phase 2 (11 open) [5].
Pembrolizumab, atezolizumab, and carboplatin are the most frequent therapies in trials for non-small cell lung carcinoma that contain ERBB2 Loss [5].
Ovarian Carcinoma +
ERBB2 Loss is an inclusion criterion in 53 clinical trials for ovarian carcinoma, of which 40 are open and 13 are closed. Of the trials that contain ERBB2 Loss and ovarian carcinoma as inclusion criteria, 31 are phase 1 (20 open), 16 are phase 1/phase 2 (14 open), and 6 are phase 2 (6 open) [5].
Pembrolizumab, gemcitabine, and olaparib are the most frequent therapies in trials for ovarian carcinoma that contain ERBB2 Loss [5].
Colorectal Carcinoma +
ERBB2 is mutated in 2.33% of colorectal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 43 clinical trials for colorectal carcinoma, of which 36 are open and 7 are closed. Of the trials that contain ERBB2 Loss and colorectal carcinoma as inclusion criteria, 27 are phase 1 (22 open), 12 are phase 1/phase 2 (10 open), and 4 are phase 2 (4 open) [5].
Pembrolizumab, spartalizumab, and atezolizumab are the most frequent therapies in trials for colorectal carcinoma that contain ERBB2 Loss [5].
Gastric Carcinoma +
ERBB2 is mutated in 10.05% of gastric carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 34 clinical trials for gastric carcinoma, of which 30 are open and 4 are closed. Of the trials that contain ERBB2 Loss and gastric carcinoma as inclusion criteria, 14 are phase 1 (11 open), 12 are phase 1/phase 2 (11 open), 6 are phase 2 (6 open), and 2 are phase 3 (2 open) [5].
Pembrolizumab, atezolizumab, and ipilimumab are the most frequent therapies in trials for gastric carcinoma that contain ERBB2 Loss [5].
Melanoma +
ERBB2 is mutated in 3.03% of melanoma patients [4].
ERBB2 Loss is an inclusion criterion in 31 clinical trials for melanoma, of which 27 are open and 4 are closed. Of the trials that contain ERBB2 Loss and melanoma as inclusion criteria, 1 is early phase 1 (1 open), 19 are phase 1 (15 open), 6 are phase 1/phase 2 (6 open), and 5 are phase 2 (5 open) [5].
Pembrolizumab, atezolizumab, and spartalizumab are the most frequent therapies in trials for melanoma that contain ERBB2 Loss [5].
Head And Neck Squamous Cell Carcinoma +
ERBB2 is mutated in 2.59% of head and neck squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 29 clinical trials for head and neck squamous cell carcinoma, of which 24 are open and 5 are closed. Of the trials that contain ERBB2 Loss and head and neck squamous cell carcinoma as inclusion criteria, 22 are phase 1 (17 open), 6 are phase 1/phase 2 (6 open), and 1 is phase 2 (1 open) [5].
Pembrolizumab, atezolizumab, and docetaxel are the most frequent therapies in trials for head and neck squamous cell carcinoma that contain ERBB2 Loss [5].
Adenocarcinoma Of The Gastroesophageal Junction +
ERBB2 is mutated in 20.96% of adenocarcinoma of the gastroesophageal junction patients [4].
ERBB2 Loss is an inclusion criterion in 27 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 22 are open and 5 are closed. Of the trials that contain ERBB2 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 11 are phase 1 (10 open), 4 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), 5 are phase 3 (4 open), and 1 is no phase specified (0 open) [5].
Placebo, pembrolizumab, and oxaliplatin are the most frequent therapies in trials for adenocarcinoma of the gastroesophageal junction that contain ERBB2 Loss [5].
Pancreatic Carcinoma +
ERBB2 is mutated in 2.2% of pancreatic carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 27 clinical trials for pancreatic carcinoma, of which 20 are open and 7 are closed. Of the trials that contain ERBB2 Loss and pancreatic carcinoma as inclusion criteria, 16 are phase 1 (11 open), 10 are phase 1/phase 2 (8 open), and 1 is phase 2 (1 open) [5].
Spartalizumab, nivolumab, and ipilimumab are the most frequent therapies in trials for pancreatic carcinoma that contain ERBB2 Loss [5].
Renal Cell Carcinoma +
ERBB2 is mutated in 0.91% of renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 26 clinical trials for renal cell carcinoma, of which 22 are open and 4 are closed. Of the trials that contain ERBB2 Loss and renal cell carcinoma as inclusion criteria, 18 are phase 1 (15 open), 6 are phase 1/phase 2 (6 open), and 2 are phase 2 (1 open) [5].
Pembrolizumab, atezolizumab, and pi3k-delta inhibitor incb050465 are the most frequent therapies in trials for renal cell carcinoma that contain ERBB2 Loss [5].
Fallopian Tube Carcinoma +
ERBB2 Loss is an inclusion criterion in 22 clinical trials for fallopian tube carcinoma, of which 17 are open and 5 are closed. Of the trials that contain ERBB2 Loss and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 14 are phase 1 (9 open), 5 are phase 1/phase 2 (5 open), and 2 are phase 2 (2 open) [5].
Olaparib, carboplatin, and gemcitabine are the most frequent therapies in trials for fallopian tube carcinoma that contain ERBB2 Loss [5].
Urothelial Carcinoma +
ERBB2 is mutated in 15.52% of urothelial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 22 clinical trials for urothelial carcinoma, of which 19 are open and 3 are closed. Of the trials that contain ERBB2 Loss and urothelial carcinoma as inclusion criteria, 13 are phase 1 (10 open), 7 are phase 1/phase 2 (7 open), and 2 are phase 2 (2 open) [5].
Pembrolizumab, atezolizumab, and epacadostat are the most frequent therapies in trials for urothelial carcinoma that contain ERBB2 Loss [5].
Small Cell Lung Carcinoma +
ERBB2 is mutated in 3.16% of small cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 21 clinical trials for small cell lung carcinoma, of which 19 are open and 2 are closed. Of the trials that contain ERBB2 Loss and small cell lung carcinoma as inclusion criteria, 9 are phase 1 (8 open), 10 are phase 1/phase 2 (9 open), and 2 are phase 2 (2 open) [5].
Pembrolizumab, gemcitabine, and olaparib are the most frequent therapies in trials for small cell lung carcinoma that contain ERBB2 Loss [5].
Gastric Adenocarcinoma +
ERBB2 is mutated in 9.57% of gastric adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 20 clinical trials for gastric adenocarcinoma, of which 15 are open and 5 are closed. Of the trials that contain ERBB2 Loss and gastric adenocarcinoma as inclusion criteria, 7 are phase 1 (5 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (3 open), and 1 is no phase specified (0 open) [5].
Placebo, pembrolizumab, and oxaliplatin are the most frequent therapies in trials for gastric adenocarcinoma that contain ERBB2 Loss [5].
Primary Peritoneal Carcinoma +
ERBB2 Loss is an inclusion criterion in 18 clinical trials for primary peritoneal carcinoma, of which 13 are open and 5 are closed. Of the trials that contain ERBB2 Loss and primary peritoneal carcinoma as inclusion criteria, 12 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (2 open) [5].
Olaparib, gemcitabine, and carboplatin are the most frequent therapies in trials for primary peritoneal carcinoma that contain ERBB2 Loss [5].
Prostate Carcinoma +
ERBB2 is mutated in 0.96% of prostate carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 17 clinical trials for prostate carcinoma, of which 13 are open and 4 are closed. Of the trials that contain ERBB2 Loss and prostate carcinoma as inclusion criteria, 12 are phase 1 (8 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].
Adenosine-a2a receptor antagonist cpi-444, enzalutamide, and mga271 are the most frequent therapies in trials for prostate carcinoma that contain ERBB2 Loss [5].
Esophageal Carcinoma +
ERBB2 is mutated in 17.78% of esophageal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 16 clinical trials for esophageal carcinoma, of which 12 are open and 4 are closed. Of the trials that contain ERBB2 Loss and esophageal carcinoma as inclusion criteria, 5 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 5 are phase 2 (5 open), and 1 is no phase specified (0 open) [5].
Pembrolizumab, adct-601, and cisplatin are the most frequent therapies in trials for esophageal carcinoma that contain ERBB2 Loss [5].
Bladder Carcinoma +
ERBB2 is mutated in 15.42% of bladder carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 15 clinical trials for bladder carcinoma, of which 12 are open and 3 are closed. Of the trials that contain ERBB2 Loss and bladder carcinoma as inclusion criteria, 11 are phase 1 (8 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].
Pembrolizumab, atezolizumab, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in trials for bladder carcinoma that contain ERBB2 Loss [5].
Breast Adenocarcinoma +
ERBB2 is mutated in 9.74% of breast adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 15 clinical trials for breast adenocarcinoma, of which 14 are open and 1 is closed. Of the trials that contain ERBB2 Loss and breast adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 4 are phase 3 (3 open), and 2 are no phase specified (2 open) [5].
Palbociclib, surgery, and sar439859 are the most frequent therapies in trials for breast adenocarcinoma that contain ERBB2 Loss [5].
Endometrial Carcinoma +
ERBB2 is mutated in 8.48% of endometrial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 15 clinical trials for endometrial carcinoma, of which 14 are open and 1 is closed. Of the trials that contain ERBB2 Loss and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 8 are phase 1 (7 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (1 open) [5].
Pembrolizumab, vistusertib, and xmab22841 are the most frequent therapies in trials for endometrial carcinoma that contain ERBB2 Loss [5].
Hepatocellular Carcinoma +
ERBB2 Loss is an inclusion criterion in 10 clinical trials for hepatocellular carcinoma, of which 8 are open and 2 are closed. Of the trials that contain ERBB2 Loss and hepatocellular carcinoma as inclusion criteria, 7 are phase 1 (5 open) and 3 are phase 1/phase 2 (3 open) [5].
Anti-muc1 car-transduced autologous t-lymphocytes, anti-pd1/ctla4 bispecific antibody xmab20717, and gamma-secretase inhibitor ly3039478 are the most frequent therapies in trials for hepatocellular carcinoma that contain ERBB2 Loss [5].
Cervical Carcinoma +
ERBB2 is mutated in 9.06% of cervical carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 9 clinical trials for cervical carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 Loss and cervical carcinoma as inclusion criteria, 6 are phase 1 (4 open) and 3 are phase 1/phase 2 (3 open) [5].
Pembrolizumab, adenosine-a2a receptor antagonist cpi-444, and cpi-006 are the most frequent therapies in trials for cervical carcinoma that contain ERBB2 Loss [5].
Head And Neck Carcinoma +
ERBB2 is mutated in 2.52% of head and neck carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 9 clinical trials for head and neck carcinoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 Loss and head and neck carcinoma as inclusion criteria, 8 are phase 1 (6 open) and 1 is phase 2 (1 open) [5].
Spartalizumab, adenosine a2a receptor antagonist nir178, and adenosine-a2a receptor antagonist cpi-444 are the most frequent therapies in trials for head and neck carcinoma that contain ERBB2 Loss [5].
Lymphoma +
ERBB2 is mutated in 1.34% of lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 9 clinical trials for lymphoma, of which 7 are open and 2 are closed. Of the trials that contain ERBB2 Loss and lymphoma as inclusion criteria, 6 are phase 1 (5 open) and 3 are phase 1/phase 2 (2 open) [5].
Gamma-secretase inhibitor ly3039478, extended release flucytosine, and gemcitabine are the most frequent therapies in trials for lymphoma that contain ERBB2 Loss [5].
Pancreatic Adenocarcinoma +
ERBB2 is mutated in 2.14% of pancreatic adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 9 clinical trials for pancreatic adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ERBB2 Loss and pancreatic adenocarcinoma as inclusion criteria, 4 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].
Anetumab ravtansine, anti-pd-l1 monoclonal antibody ly3300054, and tislelizumab are the most frequent therapies in trials for pancreatic adenocarcinoma that contain ERBB2 Loss [5].
Soft Tissue Sarcoma +
ERBB2 is mutated in 0.93% of soft tissue sarcoma patients with ERBB2 Loss present in 0.23% of all soft tissue sarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 7 clinical trials for soft tissue sarcoma, of which 6 are open and 1 is closed. Of the trials that contain ERBB2 Loss and soft tissue sarcoma as inclusion criteria, 5 are phase 1 (4 open) and 2 are phase 1/phase 2 (2 open) [5].
Adct-601, cisplatin, and taladegib are the most frequent therapies in trials for soft tissue sarcoma that contain ERBB2 Loss [5].
Glioblastoma +
ERBB2 is mutated in 1.84% of glioblastoma patients with ERBB2 Loss present in 0.06% of all glioblastoma patients [4].
ERBB2 Loss is an inclusion criterion in 7 clinical trials for glioblastoma, of which 5 are open and 2 are closed. Of the trials that contain ERBB2 Loss and glioblastoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Akt/erk inhibitor onc201, csf-1r inhibitor blz945, and extended release flucytosine are the most frequent therapies in trials for glioblastoma that contain ERBB2 Loss [5].
Pancreatic Ductal Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 6 clinical trials for pancreatic ductal adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain ERBB2 Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Pembrolizumab, pi3k-delta inhibitor incb050465, and itacitinib are the most frequent therapies in trials for pancreatic ductal adenocarcinoma that contain ERBB2 Loss [5].
Sarcoma +
ERBB2 is mutated in 1.14% of sarcoma patients with ERBB2 Loss present in 0.1% of all sarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for sarcoma, of which 3 are open and 2 are closed. Of the trials that contain ERBB2 Loss and sarcoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [5].
Pembrolizumab, adenosine-a2a receptor antagonist cpi-444, and aldesleukin prodrug nktr-214 are the most frequent therapies in trials for sarcoma that contain ERBB2 Loss [5].
Breast Invasive Ductal Carcinoma +
ERBB2 is mutated in 14.7% of breast invasive ductal carcinoma patients with ERBB2 Loss present in 0.02% of all breast invasive ductal carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for breast invasive ductal carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 Loss and breast invasive ductal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), 1 is phase 3 (1 open), and 2 are no phase specified (2 open) [5].
Surgery, cryoablation, and lumpectomy are the most frequent therapies in trials for breast invasive ductal carcinoma that contain ERBB2 Loss [5].
Peritoneal Mesothelioma +
ERBB2 Loss is an inclusion criterion in 5 clinical trials for peritoneal mesothelioma, of which 4 are open and 1 is closed. Of the trials that contain ERBB2 Loss and peritoneal mesothelioma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].
Anetumab ravtansine, everolimus, and pemetrexed are the most frequent therapies in trials for peritoneal mesothelioma that contain ERBB2 Loss [5].
Squamous Cell Lung Carcinoma +
ERBB2 is mutated in 2.31% of squamous cell lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 5 clinical trials for squamous cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 Loss and squamous cell lung carcinoma as inclusion criteria, 4 are phase 1 (4 open) and 1 is phase 1/phase 2 (1 open) [5].
Vistusertib, azd8186, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in trials for squamous cell lung carcinoma that contain ERBB2 Loss [5].
Cancer +
ERBB2 is mutated in 1.46% of cancer patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for cancer, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 Loss and cancer as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].
Pi3k/mtor inhibitor ly3023414, cisplatin, and pemetrexed are the most frequent therapies in trials for cancer that contain ERBB2 Loss [5].
Colorectal Adenocarcinoma +
ERBB2 is mutated in 4.73% of colorectal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for colorectal adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 Loss and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [5].
Pembrolizumab, e7130, and flx475 are the most frequent therapies in trials for colorectal adenocarcinoma that contain ERBB2 Loss [5].
Ductal Carcinoma In Situ +
ERBB2 is mutated in 2.86% of ductal carcinoma in situ patients [4].
ERBB2 Loss is an inclusion criterion in 4 clinical trials for ductal carcinoma in situ, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 Loss and ductal carcinoma in situ as inclusion criteria, 2 are phase 2 (1 open) and 2 are no phase specified (2 open) [5].
Radiation therapy, observation, and durvalumab are the most frequent therapies in trials for ductal carcinoma in situ that contain ERBB2 Loss [5].
Mesothelioma +
ERBB2 Loss is an inclusion criterion in 4 clinical trials for mesothelioma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 Loss and mesothelioma as inclusion criteria, 4 are phase 1 (3 open) [5].
Adct-601, cd40 agonist monoclonal antibody ro7009789, and incagn02385 are the most frequent therapies in trials for mesothelioma that contain ERBB2 Loss [5].
Nasopharyngeal Carcinoma +
ERBB2 Loss is an inclusion criterion in 4 clinical trials for nasopharyngeal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 Loss and nasopharyngeal carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].
Pembrolizumab, adct-601, and flx475 are the most frequent therapies in trials for nasopharyngeal carcinoma that contain ERBB2 Loss [5].
Peritoneal Carcinoma +
ERBB2 Loss is an inclusion criterion in 4 clinical trials for peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ERBB2 Loss and peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (3 open) [5].
Anti-b7-h4 monoclonal antibody fpa150, parp inhibitor bgb-290, and yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 are the most frequent therapies in trials for peritoneal carcinoma that contain ERBB2 Loss [5].
Acute Myeloid Leukemia +
ERBB2 is mutated in 1.09% of acute myeloid leukemia patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and acute myeloid leukemia as inclusion criteria, 3 are phase 1/phase 2 (3 open) [5].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1, gm-csf, and galinpepimut-s are the most frequent therapies in trials for acute myeloid leukemia that contain ERBB2 Loss [5].
Cholangiocarcinoma +
ERBB2 is mutated in 3.9% of cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and cholangiocarcinoma as inclusion criteria, 3 are phase 1 (2 open) [5].
Gamma-secretase inhibitor ly3039478, pi3k/mtor inhibitor ly3023414, and yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 are the most frequent therapies in trials for cholangiocarcinoma that contain ERBB2 Loss [5].
Diffuse Large B-Cell Lymphoma +
ERBB2 is mutated in 2.49% of diffuse large B-cell lymphoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Adenosine a2a receptor antagonist nir178, bay1143572, and incagn02385 are the most frequent therapies in trials for diffuse large B-cell lymphoma that contain ERBB2 Loss [5].
Esophagogastric Carcinoma +
ERBB2 is mutated in 20.53% of esophagogastric carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for esophagogastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and esophagogastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Anti-cd25-pbd antibody-drug conjugate adct-301, monoclonal microbial edp1503, and fluorouracil are the most frequent therapies in trials for esophagogastric carcinoma that contain ERBB2 Loss [5].
Malignant Ovarian Epithelial Tumor +
ERBB2 is mutated in 4.4% of malignant ovarian epithelial tumor patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for malignant ovarian epithelial tumor, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 1 (2 open) [5].
Anti-b7-h4 monoclonal antibody fpa150, yttrium y 90 anti-cdh3 monoclonal antibody ff-21101, and olaparib are the most frequent therapies in trials for malignant ovarian epithelial tumor that contain ERBB2 Loss [5].
Merkel Cell Carcinoma +
ERBB2 is mutated in 0.54% of Merkel cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 3 clinical trials for Merkel cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and Merkel cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].
Aldesleukin prodrug nktr-214, incagn02385, and peg-conjugated tlr7/8 agonist nktr-262 are the most frequent therapies in trials for Merkel cell carcinoma that contain ERBB2 Loss [5].
Non-Hodgkin Lymphoma +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 Loss and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) [5].
Fulvestrant, letrozole, and midazolam are the most frequent therapies in trials for non-hodgkin lymphoma that contain ERBB2 Loss [5].
Pleural Mesothelioma +
ERBB2 Loss is an inclusion criterion in 3 clinical trials for pleural mesothelioma, of which 2 are open and 1 is closed. Of the trials that contain ERBB2 Loss and pleural mesothelioma as inclusion criteria, 3 are phase 1 (2 open) [5].
Anetumab ravtansine, itraconazole, and mga271 are the most frequent therapies in trials for pleural mesothelioma that contain ERBB2 Loss [5].
Chronic Lymphocytic Leukemia +
ERBB2 is mutated in 2.45% of chronic lymphocytic leukemia patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 Loss and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].
Gamma-secretase inhibitor ly3039478, ror1 car-specific autologous t-lymphocytes, and prednisone are the most frequent therapies in trials for chronic lymphocytic leukemia that contain ERBB2 Loss [5].
Colon Carcinoma +
ERBB2 is mutated in 5.67% of colon carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and colon carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Adenosine a2a receptor antagonist nir178, gamma-secretase inhibitor ly3039478, and pi3k/mtor inhibitor ly3023414 are the most frequent therapies in trials for colon carcinoma that contain ERBB2 Loss [5].
Endometrial Adenocarcinoma +
ERBB2 is mutated in 9.25% of endometrial adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for endometrial adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and endometrial adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Morab-202, pi3k-delta inhibitor incb050465, and epacadostat are the most frequent therapies in trials for endometrial adenocarcinoma that contain ERBB2 Loss [5].
Esophageal Squamous Cell Carcinoma +
ERBB2 is mutated in 7.45% of esophageal squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for esophageal squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and esophageal squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Ly3143921 hydrate, porcupine inhibitor wnt974, and spartalizumab are the most frequent therapies in trials for esophageal squamous cell carcinoma that contain ERBB2 Loss [5].
Gastrointestinal Stromal Tumor +
ERBB2 is mutated in 0.85% of gastrointestinal stromal tumor patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for gastrointestinal stromal tumor that contain ERBB2 Loss [5].
Inflammatory Breast Carcinoma +
ERBB2 is mutated in 8.33% of inflammatory breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for inflammatory breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and inflammatory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Cyclophosphamide, paclitaxel, and doxorubicin are the most frequent therapies in trials for inflammatory breast carcinoma that contain ERBB2 Loss [5].
Lobular Breast Carcinoma +
ERBB2 is mutated in 12.13% of lobular breast carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for lobular breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and lobular breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Partial breast irradiation, crizotinib, and fulvestrant are the most frequent therapies in trials for lobular breast carcinoma that contain ERBB2 Loss [5].
Multiple Myeloma +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and multiple myeloma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1 and jak1 inhibitor incb052793 are the most frequent therapies in trials for multiple myeloma that contain ERBB2 Loss [5].
Myelodysplastic Syndromes +
ERBB2 is mutated in 0.76% of myelodysplastic syndromes patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and myelodysplastic syndromes as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].
Autologous nkg2d car-expressing t-lymphocytes cm-cs1 and jak1 inhibitor incb052793 are the most frequent therapies in trials for myelodysplastic syndromes that contain ERBB2 Loss [5].
Prostate Adenocarcinoma +
ERBB2 is mutated in 0.87% of prostate adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 2 clinical trials for prostate adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Odm-209, ipatasertib, and rucaparib are the most frequent therapies in trials for prostate adenocarcinoma that contain ERBB2 Loss [5].
Ureter Urothelial Carcinoma +
ERBB2 Loss is an inclusion criterion in 2 clinical trials for ureter urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 Loss and ureter urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Gsk3326595, pi3k-delta inhibitor incb050465, and itacitinib are the most frequent therapies in trials for ureter urothelial carcinoma that contain ERBB2 Loss [5].
High Grade Ovarian Serous Adenocarcinoma +
ERBB2 is mutated in 3.48% of high grade ovarian serous adenocarcinoma patients with ERBB2 Loss present in 0.4% of all high grade ovarian serous adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for high grade ovarian serous adenocarcinoma that contain ERBB2 Loss [5].
Neuroendocrine Carcinoma +
ERBB2 is mutated in 2.27% of neuroendocrine carcinoma patients with ERBB2 Loss present in 0.15% of all neuroendocrine carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and neuroendocrine carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Ferumoxytol, liposomal irinotecan, and veliparib are the most frequent therapies in trials for neuroendocrine carcinoma that contain ERBB2 Loss [5].
Acute Lymphoblastic Leukemia +
ERBB2 is mutated in 0.68% of acute lymphoblastic leukemia patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Ror1 car-specific autologous t-lymphocytes is the most frequent therapy in trials for acute lymphoblastic leukemia that contain ERBB2 Loss [5].
Adenoid Cystic Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in trials for adenoid cystic carcinoma that contain ERBB2 Loss [5].
Anaplastic Astrocytoma +
ERBB2 is mutated in 1.33% of anaplastic astrocytoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for anaplastic astrocytoma that contain ERBB2 Loss [5].
B-Cell Neoplasm +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for B-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and B-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in trials for B-cell neoplasm that contain ERBB2 Loss [5].
Bladder Urothelial Carcinoma +
ERBB2 is mutated in 16.45% of bladder urothelial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gsk3326595 is the most frequent therapy in trials for bladder urothelial carcinoma that contain ERBB2 Loss [5].
Breast Lobular Carcinoma In Situ +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and breast lobular carcinoma in situ as inclusion criteria, 1 is no phase specified (1 open) [5].
Observation and radiation therapy are the most frequent therapies in trials for breast lobular carcinoma in situ that contain ERBB2 Loss [5].
Cervical Squamous Cell Carcinoma +
ERBB2 is mutated in 6.5% of cervical squamous cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Porcupine inhibitor wnt974 and spartalizumab are the most frequent therapies in trials for cervical squamous cell carcinoma that contain ERBB2 Loss [5].
Classical Hodgkin Lymphoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Flx475 and pembrolizumab are the most frequent therapies in trials for classical hodgkin lymphoma that contain ERBB2 Loss [5].
Clear Cell Renal Cell Carcinoma +
ERBB2 is mutated in 1.31% of clear cell renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for clear cell renal cell carcinoma that contain ERBB2 Loss [5].
Diffuse Gastric Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for diffuse gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and diffuse gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Crizotinib and fulvestrant are the most frequent therapies in trials for diffuse gastric adenocarcinoma that contain ERBB2 Loss [5].
Esophageal Adenocarcinoma +
ERBB2 is mutated in 19.46% of esophageal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ewing Sarcoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Pen-866 is the most frequent therapy in trials for Ewing sarcoma that contain ERBB2 Loss [5].
Extrahepatic Cholangiocarcinoma +
ERBB2 is mutated in 5.8% of extrahepatic cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lenvatinib and pembrolizumab are the most frequent therapies in trials for extrahepatic cholangiocarcinoma that contain ERBB2 Loss [5].
Fallopian Tube Clear Cell Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for fallopian tube clear cell adenocarcinoma that contain ERBB2 Loss [5].
Fallopian Tube Endometrioid Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for fallopian tube endometrioid adenocarcinoma that contain ERBB2 Loss [5].
Gallbladder Carcinoma +
ERBB2 is mutated in 11.11% of gallbladder carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lenvatinib and pembrolizumab are the most frequent therapies in trials for gallbladder carcinoma that contain ERBB2 Loss [5].
Germ Cell Tumor +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Palbociclib is the most frequent therapy in trials for germ cell tumor that contain ERBB2 Loss [5].
Hematopoietic And Lymphoid Malignancy +
ERBB2 is mutated in 2.7% of hematopoietic and lymphoid malignancy patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Ky1044 and atezolizumab are the most frequent therapies in trials for hematopoietic and lymphoid malignancy that contain ERBB2 Loss [5].
High Grade Fallopian Tube Serous Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for high grade fallopian tube serous adenocarcinoma that contain ERBB2 Loss [5].
Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +
ERBB2 is mutated in 11.27% of infiltrating renal pelvis and ureter urothelial carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gsk3326595 is the most frequent therapy in trials for infiltrating renal pelvis and ureter urothelial carcinoma that contain ERBB2 Loss [5].
Intrahepatic Cholangiocarcinoma +
ERBB2 is mutated in 2.64% of intrahepatic cholangiocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lenvatinib and pembrolizumab are the most frequent therapies in trials for intrahepatic cholangiocarcinoma that contain ERBB2 Loss [5].
Leiomyosarcoma +
ERBB2 is mutated in 1.31% of leiomyosarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and leiomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in trials for leiomyosarcoma that contain ERBB2 Loss [5].
Lung Adenocarcinoma +
ERBB2 is mutated in 4.38% of lung adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Anetumab ravtansine and itraconazole are the most frequent therapies in trials for lung adenocarcinoma that contain ERBB2 Loss [5].
Lung Carcinoma +
ERBB2 is mutated in 2.72% of lung carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ifetroban sodium and placebo are the most frequent therapies in trials for lung carcinoma that contain ERBB2 Loss [5].
Malignant Ovarian Clear Cell Tumor +
ERBB2 is mutated in 5.88% of malignant ovarian clear cell tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for malignant ovarian clear cell tumor that contain ERBB2 Loss [5].
Malignant Pleural Mesothelioma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Carboplatin and rebastinib tosylate are the most frequent therapies in trials for malignant pleural mesothelioma that contain ERBB2 Loss [5].
Malignant Thyroid Gland Neoplasm +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Mga271 and ipilimumab are the most frequent therapies in trials for malignant thyroid gland neoplasm that contain ERBB2 Loss [5].
Mantle Cell Lymphoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Ror1 car-specific autologous t-lymphocytes is the most frequent therapy in trials for mantle cell lymphoma that contain ERBB2 Loss [5].
NUT Midline Carcinoma Of The Head And Neck +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for NUT midline carcinoma of the head and neck, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and NUT midline carcinoma of the head and neck as inclusion criteria, 1 is phase 1 (0 open) [5].
Mk-8628 is the most frequent therapy in trials for NUT midline carcinoma of the head and neck that contain ERBB2 Loss [5].
Ovarian Endometrioid Tumor +
ERBB2 is mutated in 5.42% of ovarian endometrioid tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for ovarian endometrioid tumor that contain ERBB2 Loss [5].
Ovarian Epithelial Tumor +
ERBB2 is mutated in 2.35% of ovarian epithelial tumor patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Sacituzumab govitecan is the most frequent therapy in trials for ovarian epithelial tumor that contain ERBB2 Loss [5].
Pancreatic Neuroendocrine Neoplasm +
ERBB2 is mutated in 1.44% of pancreatic neuroendocrine neoplasm patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Everolimus is the most frequent therapy in trials for pancreatic neuroendocrine neoplasm that contain ERBB2 Loss [5].
Papillary Renal Cell Carcinoma +
ERBB2 is mutated in 0.86% of papillary renal cell carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for papillary renal cell carcinoma that contain ERBB2 Loss [5].
Primary Peritoneal Serous Adenocarcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ipatasertib and rucaparib are the most frequent therapies in trials for primary peritoneal serous adenocarcinoma that contain ERBB2 Loss [5].
Renal Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for renal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and renal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Ky1044 and atezolizumab are the most frequent therapies in trials for renal carcinoma that contain ERBB2 Loss [5].
Renal Pelvis Urothelial Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gsk3326595 is the most frequent therapy in trials for renal pelvis urothelial carcinoma that contain ERBB2 Loss [5].
Renal Pelvis And Ureter Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for renal pelvis and ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and renal pelvis and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Atezolizumab is the most frequent therapy in trials for renal pelvis and ureter carcinoma that contain ERBB2 Loss [5].
Rhabdomyosarcoma +
ERBB2 is mutated in 0.86% of rhabdomyosarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Pen-866 is the most frequent therapy in trials for rhabdomyosarcoma that contain ERBB2 Loss [5].
Small Intestinal Adenocarcinoma +
ERBB2 is mutated in 14.75% of small intestinal adenocarcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for small intestinal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and small intestinal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
T-Cell And NK-Cell Neoplasm +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 Loss and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].
Gamma-secretase inhibitor ly3039478 and prednisone are the most frequent therapies in trials for T-cell and NK-cell neoplasm that contain ERBB2 Loss [5].
Thymoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for thymoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and thymoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Thyroid Gland Carcinoma +
ERBB2 is mutated in 1.51% of thyroid gland carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Vistusertib and selumetinib are the most frequent therapies in trials for thyroid gland carcinoma that contain ERBB2 Loss [5].
Thyroid Gland Follicular Carcinoma +
ERBB2 Loss is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Sacituzumab govitecan is the most frequent therapy in trials for thyroid gland follicular carcinoma that contain ERBB2 Loss [5].
Urethral Carcinoma +
ERBB2 is mutated in 8.0% of urethral carcinoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for urethral carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and urethral carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Atezolizumab is the most frequent therapy in trials for urethral carcinoma that contain ERBB2 Loss [5].
Uterine Corpus Carcinosarcoma +
ERBB2 is mutated in 6.77% of uterine corpus carcinosarcoma patients [4].
ERBB2 Loss is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 Loss and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Adenosine-a2a receptor antagonist cpi-444, cpi-006, and pembrolizumab are the most frequent therapies in trials for uterine corpus carcinosarcoma that contain ERBB2 Loss [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
